Juno Therapeutics Inc.

https://www.junotherapeutics.com

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, and The National Cancer Institute. *

	Start	2015-05-11 existent
	Group	Bristol Myers Squibb (BMS) (Group)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Person	Bishop, Hans E. (Juno Therapeutics 201601 CEO + Co-Founder before Dendreon + Bayer + GW + SKB)

	Region	Seattle, WA
	Country	United States (USA)
	Street	307 Westlake Avenue North Suite 300
	City	98109 Seattle, WA
	Tel	+1-206-582-1600
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	18,215,000 (revenue, consolidated (2015) 2015-12-31)
	Profit	-239,376,000 (2015-12-31)
	Cash	943,411,000 (2015-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10